FDA bans products from China plant used by Big Pharma players

A Chinese drug-ingredient maker who has produced active ingredients for some of the big guns in pharma now faces an FDA ban in the U.S. The agency added Zhejiang Hisoar Pharmaceutical to its import alert list after finding violations at a plant in Taizhou, Bloomberg reports. The company has made APIs for drugmakers including Novartis ($NVS), Sanofi ($SNY) and Pfizer ($PFE). More from FiercePharmaManufacturing